Five-year OS in NK-AML was 62% (95 CI: 55–69%) compared to CBF-AML (80%; CI: 74–85%), KMT2A (58%; CI: 50–65%) and other AK-AML (50%; 55–69%) (Figure S2A). Here, CEBPZ is linked to acute myeloid leukemia.